Biocon in pact with Japan’s Yoshindo to commercialise two biosimilar assets

Yoshindo will get exclusive commercialisation rights in Japan for bUstekinumab and bDenosumab, developed and manufactured by Biocon Biologics, for an addressable market opportunity of over $700 million.

Priyanka Sharma
First Published17 Oct 2022, 04:50 PM IST
Biocon in pact with Japan’s Yoshindo to commercialise two biosimilar assets. (Photo: Mint)
Biocon in pact with Japan’s Yoshindo to commercialise two biosimilar assets. (Photo: Mint)

NEW DELHI: Biocon Biologics has entered into a strategic out-licensing agreement with Japanese pharmaceuticals company, Yoshindo Inc., for commercialising bUstekinumab and bDenosumab, two of its biosimilar assets in the pipeline, in the Japanese market.

As part of the agreement, Yoshindo will get exclusive commercialisation rights in Japan for bUstekinumab and bDenosumab, developed and manufactured by Biocon Biologics, for an addressable market opportunity of over $700 million.

Shreehas Tambe, deputy chief executive officer, said, “We are excited to partner with Yoshindo to commercialise two of our pipeline biosimilar products, bUstekinumab and bDenosumab, in Japan. This partnership is testament to Biocon Biologics’ proven capabilities in R&D, global scale manufacturing and quality compliance. Once approved, these products will expand our offering of affordable, high quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas.”

“The strategic partnership with Yoshindo will build upon Biocon Biologics’ successful progress in its global development programmes for these two biosimilar assets. Clinical trials for these two assets commenced in FY22 and include both phase 1 and phase 3 clinical trials backed by robust pre-clinical CMC packages,” the company said in a statement.

Biocon Biologics, part of pharma major Biocon Ltd., will receive an upfront licence fee as well as additional payments on the achievement of certain development milestones over the next few years. The financial terms of the agreement were not disclosed.

Ustekinumab, a biosimilar referencing Stelara, is a monoclonal antibody used to treat several autoimmune conditions, including psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. Denosumab, a biosimilar referencing Prolia, is a monoclonal antibody for the treatment of osteoporosis.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.MoreLess
First Published:17 Oct 2022, 04:50 PM IST
HomeCompaniesNewsBiocon in pact with Japan’s Yoshindo to commercialise two biosimilar assets

Most Active Stocks

Tata Steel

167.05
03:57 PM | 16 JUL 2024
0.25 (0.15%)

Oil & Natural Gas Corporation

322.40
03:58 PM | 16 JUL 2024
-0.15 (-0.05%)

Bandhan Bank

198.30
03:41 PM | 16 JUL 2024
2.95 (1.51%)

Coal India

512.35
03:59 PM | 16 JUL 2024
14.4 (2.89%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

Natco Pharma

1,281.05
03:59 PM | 16 JUL 2024
73.2 (6.06%)

Century Textiles & Industries

2,217.55
03:48 PM | 16 JUL 2024
116.85 (5.56%)

Tata Teleservices Maharashtra

81.33
03:54 PM | 16 JUL 2024
4.23 (5.49%)

India Cements

323.05
03:55 PM | 16 JUL 2024
15.8 (5.14%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    75,246.00928.00
    Chennai
    75,099.00344.00
    Delhi
    74,806.00-460.00
    Kolkata
    75,466.00419.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.76/L0.00
    Kolkata
    104.95/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsCibilPremiumMint Shorts